World Investment Advisors Lowers Position in IQVIA Holdings Inc. (NYSE:IQV)

World Investment Advisors decreased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 2.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 59,989 shares of the medical research company’s stock after selling 1,760 shares during the period. World Investment Advisors’ holdings in IQVIA were worth $11,788,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in IQV. Massachusetts Financial Services Co. MA raised its stake in IQVIA by 5.6% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 142,249 shares of the medical research company’s stock worth $27,953,000 after acquiring an additional 7,546 shares during the period. Headlands Technologies LLC raised its position in shares of IQVIA by 397.0% during the 4th quarter. Headlands Technologies LLC now owns 1,675 shares of the medical research company’s stock valued at $329,000 after purchasing an additional 1,338 shares during the period. Geode Capital Management LLC lifted its stake in shares of IQVIA by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock valued at $818,315,000 after buying an additional 77,981 shares in the last quarter. HighPoint Advisor Group LLC boosted its holdings in IQVIA by 22.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,133 shares of the medical research company’s stock worth $428,000 after buying an additional 395 shares during the period. Finally, Franklin Resources Inc. increased its stake in IQVIA by 4.7% in the 4th quarter. Franklin Resources Inc. now owns 525,489 shares of the medical research company’s stock worth $103,264,000 after buying an additional 23,682 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.9 %

Shares of IQV opened at $174.52 on Thursday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 52-week low of $169.11 and a 52-week high of $252.88. The company has a market cap of $30.77 billion, a PE ratio of 23.27, a P/E/G ratio of 1.99 and a beta of 1.50. The business has a fifty day moving average of $191.43 and a 200 day moving average of $204.92.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on IQV shares. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. UBS Group reduced their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Citigroup dropped their target price on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Finally, Robert W. Baird reduced their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.